Therapy for common parasitic diseases in pregnancy in the United States: A review and a survey of obstetrician/gynecologists' level of knowledge about these diseases

Obstetrical and Gynecological Survey

Volumn 60, Issue 6, 2005, Pages 386-393

  Jones, Jeffrey L ^a   Schulkin, Jay ^b   Maguire, James H ^c  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; CLINDAMYCIN; COTRIMOXAZOLE; MEBENDAZOLE; MEPACRINE; METRONIDAZOLE; NICLOSAMIDE; NITAZOXANIDE; PAROMOMYCIN; PRAZIQUANTEL; PYRANTEL EMBONATE; TINIDAZOLE;

AMEBIASIS; ASCARIASIS; CRYPTOSPORIDIOSIS; CYCLOSPORIASIS; CYSTICERCOSIS; DIARRHEA; DRUG SAFETY; EMBRYOTOXICITY; FEMALE; FOOD CONTAMINATION; GIARDIASIS; HEALTH SURVEY; HUMAN; MEDICAL SPECIALIST; PARASITOSIS; PREGNANCY; REVIEW; TAENIASIS; TOXOPLASMOSIS; TRICHINOSIS; UNITED STATES; VAGINITIS; WATER CONTAMINATION;

AMEBIASIS; ANTIPARASITIC AGENTS; ANTIPROTOZOAL AGENTS; ASCARIASIS; CRYPTOSPORIDIOSIS; CYCLOSPORIASIS; CYSTICERCOSIS; FEMALE; GIARDIASIS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; QUESTIONNAIRES; TAENIASIS; TRICHINOSIS; UNITED STATES;

EID: 19744380878     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ogx.0000162430.67144.6b     Document Type: Review

References (68)

1. Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol 2001;154: 357-365.
2. Busby JC, Roberts T. ERS updates of US foodborne disease costs for seven pathogens. Food review (Sept-Dec) 1996;19:20-25.
3. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:16.
4. Centers for Disease Control and Prevention. CDC Surveillance Summaries, May 26, 2000. MMWR Morb Mortal Wkly Rep 2000;49.
5. Centers for Disease Control and Prevention. CDC Surveillance Summaries, Nov. 22, 2002. MMWR Morb Mortal Wkly Rep 2002;51.
6. MacKenzie WR, Hoxie NJ, Proctor ME, et al. A massive outbreak in Milwaukee of Cryptosporidium infection transmitted through the public water supply. N Engl J Med 1994;331:161-167.
7. Jones JL, Lopez A, Wahlquist SP, Nadle J, Wilson. Emerging infections program FoodNet Working Group. Survey of clinical laboratory practices for parasitic diseases. Clin Infect Dis 2004;38:S198-S202.
8. Morin CA, Roberts CL, Mshar PA, Addiss DG, Hadler JL. What do physicians know about cryptosporidiqsis? A survey of Connecticut physicians. Arch Intern Med 1997;157:1017-1022.
9. Rossingol JFA, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001;184:103-106.
10. Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomized controlled trial. Lancet 2002;360:1375-1380.
11. Ortiz JJ, Ayoub A, Gargala G, Chegne NL, Favennec L. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther 2001;15:1409-1415.
12. US Food and Drug Administration. Alinia prescribing information. Available at: http://www.fda.gov/cder/foi/label/2002/21498 Alinia lbl.pdf. Accessed November 4, 2004.
13. Nitazoxanide (investigators brochure). Tampa, FL: Romark Laboratories; 2000:45-78.
14. Murphy JR, Friedmann JC. Pre-clinical toxicology of nitazoxanide-a new antiparasitic compound. J Appl Toxicol 1985; 5:49-52.
15. Hoveyda F, Davies WAR, Hunter PR. A case of cryptosporidiosis in pregnancy. Eur J Clin Microbiol 2002;21:637-638.
16. Drugs for parasitic infections. Med Lett Drugs Ther 2004; (1189):1-12. Available at: www.medicalletter.org.
17. Finegold SM. Metronidazole. Ann Intern Med 1980;93:585-587.
18. Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dockery MB. Lack of evidence of cancer due to use of metronidazole. N Engl J Med 1979;301:519-522.
19. Flagyl. Product information. GD Searle; 2000.
20. Piper MN, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 1993;82: 348-352.
21. Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole. Br J Obstet Gynaecol 1998;105:322-327.
22. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a metaanalysis. Am J Obstet Gynecol 1995;172:525-529.
23. Caro-Paton T, Carvajal A, Martin de Diego I, et al. Is metronidazole teratogenic? A metaanalysis. Br J Clin Pharmacol 1997;44:179-182.
24. Lopez Nigro MM, Gadano AB, Carballo MA. Evaluation of genetic damage induced by a nitroimidazole derivative in human lymphocytes: tinidazole (TNZ). Toxicology in Vitro 2001;15:209-213.
25. Sawyer PR, Brodgen RN, Pinder RM, Speight TM, Avery GS. Tinidazole: a review of its antiprotozoal activity and therapeutic efficacy. Drugs 1976;11:423-440.
26. Roe FJC. Safety of nitroimidazoles. Scand J Infect Dis 1985; 46(suppl):72-81.
27. Safety of antimicrobial drugs in pregnancy. Med Lett Drugs Ther 1987;29:61-63.
28. American College of Obstetricians and Gynecologists. Antimicrobial therapy for obstetric patients. Educational Bulletin. March 1998, No. 245.
29. Hoge CW, Shlim DR, Ghimire M, et al. Placebo-controlled trial of cotrimoxazole for Cyclospora infections among travelers and foreign residents in Nepal. Lancet 1995;345:691-693.
30. Heckel GP. Chemotherapy during pregnancy. Danger of fetal injury from sulfanilamide and its derivatives. JAMA 1941;117: 1314-1316.
31. Ginzler AM, Cherner C. Toxic manifestations in the newborn infant following placental transmission of sulfanilamide. With a report of 2 cases simulating erythroblastosis fetalis. Am J Obstet Gynecol 1942;44:46-55.
32. Lucey JF, Driscol TJ Jr. Hazard to newborn infants of administration of long-acting sulfonamides to pregnant women. Pediatrics 1959;24:498-499.
33. Kantor HI, Sutherland DA, Leonard JT, Kamholz FH, Fry ND, White WL. Effect on bilirubin metabolism in the newborn of sulfisoxazole administration to the mother. Obstet Gynecol 1961;17:494-500.
34. Dunn PM. The possible relationship between the maternal administration of sulphamethoxypryidazine and hyperbilirubinaemia in the newborn. J Obstet Gynaecol Br Commonw 1964;71:128-131.
35. Brumfitt W, Pursell R. Trimethoprim-sulfamethoxazole in the treatment of bacteriuria in women. J Infect Dis 1973; 128(suppl):S657-S663.
36. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001;184:381-384.
37. Tanyuksel M, Petri WA Jr. Laboratory diagnosis of amebiasis. Clin Microbiol Rev 2003;16:1713-1729.
38. Albenza. Product information. SmithKline Beecham Pharmaceuticals; 2001.
39. Mantovani A, Ricciardi C, Stazi AV, Ricciardi C. Effects of albendazole on the early phases of rat organogenesis in vivo: preliminary results [Abstract]. Teratology 1992;46:25A.
40. Mantovani A, Ricciardi C, Stazi AV, Marci C. Effects observed on gestational day 13 in rat embryos exposed to albendazole. Reprod Toxicol 1995;9:265-273.
41. Rossignol JF, Friedman JC, Arrouseau M, DiCullo CJ. Albendazole: animal toxicology. Compendium de Investigaciones Clinicas Latino Americanas 1981;suppl 1:56-60.
42. Whittaker SB, Faustman EM. Effects of albendazole and albendazole sulfoxide on cultures of differentiating rodent embryonic cells. Toxicol Appl Pharmacol 1991;190:73-84.
43. Whittaker SB, Faustman EM. Effects of benzimidazole analogs on cultures of differentiating rodent embryonic cells. Toxicol Appl Pharmacol 1992;113:144-151.
44. Vermox. Product information. McNeil Consumer; 2000.
45. Torlesse H, Hodges M. Anthelminthic treatment and haemoglobin concentrations during pregnancy. Lancet 2000;356:1083.
46. de Silva NR, Sirisena JLGJ, Gunasekera DPS, Ismail MM, de Silva HJ. Effect of mebendazole therapy during pregnancy on birth outcome. Lancet 1999;353:1145-1149.
47. Bradley M, Horton J. Assessing the risk of benzimidazole therapy during pregnancy. Trans R Soc Trop Med Hyg 2001; 95:72-73.
48. Cowden J, Hotez P. Mebendazole and albendazole treatment of geohelminth infections in children and pregnant women. Pediatr Infect Dis J 2000;659-660.
49. Report of the Informal Consultation on Hookworm Infection and Anaemia in Girls and Women. Geneva: World Health Organization; 1996:40.
50. Owaki Y, Sakai T, Momiyama H. Teratological studies on pyrantel pamoate in rats. Oyo Yakuri 1971;5:41-50.
51. As cited in Shepard TH. Catalog of Teratogenic Agents, 6th ed. Baltimore: Johns Hopkins University Press; 1989:536.
52. Owaki Y, Sakai T, Momiyama H. Teratological studies on pyrantel pamoate in rabbits. Oyo Yakuri 1971;5:33-39.
53. As cited in Shepard TH. Catalog of Teratogenic Agents, 6th ed. Baltimore: Johns Hopkins University Press; 1989:536.
54. Ellis CJ. Antiparasitic agents in pregnancy. Clin Obstet Gynaecol 1986;13:269-275.
55. Anderson S. Travel advice for women. In: Jong EC, McMullen R, eds. Travel and Tropical Medicine Manual, 3rd ed. Philadelphia: WB Saunders; 2003:215.
56. Centers for Disease Control and Prevention. Trichinellosis surveillance-United States, 1997-2001. MMWR Morb Mortal Wkly Rep 2003;52:1-8.
57. Sorvillo FJ, Portigal L, DeGiorgio C, et al. Cysticercosis-related deaths, California. Emerg Infect Dis 2004;10:465-469.
58. Townes JM, Hoffmann CJ, Kohn MA. Neurocysticercosis in Oregon, 1995-2000. Emerg Infect Dis 2004;10:508-510.
59. Medina MT, Rosas E, Rubio-Donnadieu F, Sorvillo FJ. Neurocysticercosis as the main cause of late-onset epilepsy in Mexico. Arch Intern Med 1990;150:325-327.
60. Bern C, Garcia HH, Evans C, et al. Magnitude of the disease burden from neurocysticercosis in a developing country. Clin Infect Dis 1999;29:1203-1209.
61. Garcia HH, Evans CA, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002;15:747-756.
62. Biltricide. Product information. Bayer Corp; 1999.
63. Frohberg H. Results of toxicological studies on praziquantel. Arzneimittelforschung 1984;34:1137-1144.
64. Report of the WHO informal consultation on the use of praziquantel during pregnancy/lactation and albendazole/mebendazole in children under 24 months. Geneva: World Health Organization; April 8-9, 2002:3-48. Available at: http://whqlibdoc.who.int/hq/2003/WHO CDS CPE PVC 2002.4.pdf. Accessed February 23, 2005.
65. Volkheimer G. Intestinal helminthiasis-general practice problem of the gastroenterologist. Z Gastroenterol 1996;34:534-541.
66. de Silva N, Guyatt H, Bundy D. Anthelmintics. A comparative review of their clinical pharmacology. Drugs 1997;53:769-788.
67. Epilnfo version 3.3, Centers for Disease Control and Prevention 2004. Available at: http://www.cdc.gov/epiinfo/. Accessed November 4, 2004.
68. Jones JL, Lopez A, Wilson M, Schulkin J, Gibbs R. Congenital toxoplasmosis: a review. Obstet Gynecol Surv 2001;56:296-305.